4-HO-DiPT

Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act)¹⁰ as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are criminally punishable.¹² Possession is prohibited but not subject to criminal penalty.¹¹¹² Use is permitted only for industrial and scientific purposes.¹¹

The substance is prohibited in Japan. The exact molecule is expressly listed as a designated drug (4-OH-DIPT) and its salts in the current list and consolidated ordinance; the separate current narcotic decree lists a distinct 5-methoxy positional tryptamine compound. Under PMD Act Article 76-4, ordinary recreational manufacture, import, sale, transfer, possession, purchase, receipt and use are prohibited outside legally defined medical or other permitted uses.

Norway's current Narkotikalisten lists 4-Hydroksy DiPT as 4-hydroksy-N,N-diisopropyltryptamin (also expressed as 3-[2-(diisopropylamino)etyl]-1H-indol-4-ol). Narkotikaforskriften § 3 treats substances listed in the Narkotikalisten as narcotics. Section 5 prohibits possession or use of narcotics without lawful authority.

4-HO-DiPT is expressly named in Singapore's amendment to the Misuse of Drugs Act schedules. The instrument identifies it as 4-Hydroxy-N,N-diisopropyltryptamine and gives 4-Hydroxy-DiPT as an alternate name.

4-HO-DiPT is a narcotic in Sweden. Section 2 of Förordning (1992:1554) om kontroll av narkotika provides that the substances set out in annex 1 are narcotics under Narkotikastrafflag (1968:64), and the hallucinogens part of that annex names 3-(2-[di(propan-2-yl)amino]etyl)-1H-indol-4-ol (4-HO-DIPT). The consolidated Läkemedelsverket narcotics lists place the substance in Swedish förteckning I, which covers substances, plant material and fungi that normally have no medical use. Narcotics may be imported, exported, manufactured, offered for sale, transferred or possessed only for a medical, scientific, other especially pressing purpose of public benefit, or industrial purpose, and possession is confined to the categories set out in section 7 of Lag (1992:860) om kontroll av narkotika. Section 1 of Narkotikastrafflag punishes unauthorised transfer, manufacture intended for misuse, acquisition for transfer, specified handling not intended for personal use, and possession, use or other handling with imprisonment for up to three years; selling, or handling narcotics intended for sale, carries imprisonment of at least six months and at most three years. The substance was instead a hälsofarlig vara under Lagen om förbud mot vissa hälsofarliga varor from March 1, 2005 under regulation SFS 2005:26, and SFS 2019:332 removed it from that annex on July 2, 2019, the day SFS 2019:331 and HSLF-FS 2019:16 placed it in the narcotics annex and lists.

4-HO-DiPT is not separately named in the current Swiss list, but PubChem identifies the 4-hydroxy-N,N-diisopropyltryptamine structure and current BetmVV-EDI Annex 5 Verzeichnis d item 266 generically covers that substitution pattern. The rule expressly excludes industrial and scientific use while expressly not excluding private use. The listing constitutes generic and blanket coverage under Verzeichnis d; Verzeichnis d prohibits the substance, and Article 8 provides an exception-authorisation framework.

Controlled as a Class A substance under the Misuse of Drugs Act 1971 due to the tryptamine catch-all clause, which covers substituted tryptamines regardless of whether they are individually named in the schedules.³⁶

4-HO-DiPT is expressly listed as 3-{2-[di(propan-2-yl)amino]ethyl}-1H-indol-4-ol in the annex to Valtioneuvoston asetus 1130/2014, and section 1 of that decree makes the annex substances the psychoactive substances banned from the consumer market. Under section 5 of Huumausainelaki 373/2008, manufacture, import into Finland, storage, offering for sale, and supply of a consumer-market-banned psychoactive substance are prohibited. Section 23 b of the same Act allows a university, a scientific research institute, or a business operator to import and store such a substance for research or for justified industrial activity after notifying the Finnish Medicines Agency. The substance does not appear in annexes I to V of the narcotics decree 543/2008, so it is not a narcotic under Finnish law. The current annex applies from 10 July 2026 under Valtioneuvoston asetus 650/2026.

Not scheduled at the federal level. However, it may be considered an analogue of psilocin (4-HO-DMT) or 5-MeO-DiPT, potentially subjecting purchase, sale, or possession to prosecution under the Federal Analogue Act when intended for human consumption. The DEA proposed scheduling in January 2022 but withdrew the proposal in July 2022 following public response.³⁷